Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 10/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.39 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.39 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625399 | 0.89 | MTOR (0.41) | MTORPIK3R1PIK3CARICTORRPTOR | |
| SCHEMBL2625398 | 0.76 | MTOR (0.62) | MTORPIK3CARICTORRPTORMAPKAP1 | |
| SCHEMBL2632645 | 0.75 | MTOR (0.61) | MTORPIK3CARPTORMLST8 | |
| SCHEMBL7943111 | 0.74 | PIK3CA (0.44) | MTORPIK3R1PIK3CARICTORRPTOR | |
| SCHEMBL10221494 | 0.73 | MTOR (0.39) | MTORPIK3R1PIK3CARICTORRPTOR | |
| SCHEMBL2632646 | 0.72 | MTOR (0.44) | MTORPIK3CARPTORMLST8 | |
| SCHEMBL2625402 | 0.72 | MTOR (0.39) | MTORPIK3R1PIK3CARICTORRPTOR | |
| SCHEMBL2632857 | 0.71 | MTOR (0.40) | MTORPIK3R1PIK3CARICTORRPTOR | |
| SCHEMBL2625403 | 0.69 | PIK3R1 (0.44) | MTORPIK3R1PIK3CAATR | |
| SCHEMBL30531819 | 0.67 | MTOR (0.41) | MTORLRRK2ATRATRIPCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163763-B2 | Pyrimidine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069357-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, TYMS, DTYMK | MTOR 1/4885PIK3R1 151/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.